Evidence map›Paper›PMID 31671788›Full record

ReviewInternational journal of molecular sciences2019

Substantial Overview on Mesenchymal Stem Cell Biological and Physical Properties as an Opportunity in Translational Medicine.

Heba Abdelrazik, Emanuele Giordano, Giovanni Barbanti Brodano, Cristiana Griffoni, Elena De Falco, Alessandra Pelagalli

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Heba AbdelrazikDepartment of Clinical Pathology, Cairo University, Cairo 1137, Egypt. hebanabil@gmail.com.
Emanuele GiordanoDepartment of Electrical, Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, 47522 Cesena, Italy. emanuele.giordano@unibo.it.
Giovanni Barbanti BrodanoDepartment of Oncological and Degenerative Spine Surgery, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. giovanni@barbantibrodano.com.
Cristiana GriffoniDepartment of Oncological and Degenerative Spine Surgery, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. cgriffoni@hotmail.com.
Elena De FalcoDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy. elena.defalco@uniroma1.it.ORCID 0000-0002-5220-0587
Alessandra PelagalliDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", 80131 Naples, Italy. alpelaga@unina.it.ORCID 0000-0002-1133-4300
Istituto Ortopedico Rizzoli · ITCairo University · EGClinica Mediterranea · ITInstitute of Biostructure and Bioimaging · ITLaboratori Guglielmo Marconi (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSC) have piqued worldwide interest for their extensive potential to treat a large array of clinical indications, their unique and controversial immunogenic and immune modulatory properties allowing ample discussions and debates for their possible applications. Emerging data demonstrating that the interaction of biomaterials and physical cues with MSC can guide their differentiation into specific cell lineages also provide new interesting insights for further MSC manipulation in different clinical applications. Moreover, recent discoveries of some regulatory molecules and signaling pathways in MSC niche that may regulate cell fate to distinct lineage herald breakthroughs in regenerative medicine. Although the advancement and success in the MSC field had led to an enormous increase in the amount of ongoing clinical trials, we still lack defined clinical therapeutic protocols. This review will explore the exciting opportunities offered by human and animal MSC, describing relevant biological properties of these cells in the light of the novel emerging evidence mentioned above while addressing the limitations and challenges MSC are still facing.

Indexed as

AnimalsAutocrine CommunicationBiocompatible MaterialsBone DiseasesBone RegenerationCell DifferentiationCell LineageCell PlasticityHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationParacrine CommunicationRegenerative MedicineSignal TransductionTissue ScaffoldsTranslational Research, BiomedicalBiocompatible Materials3D scaffoldsangiogenesisbiomaterialsbone regenerationimmune modulationmesenchymal stem cells (MSC)translational medicine

Identifiers

PMID31671788
PMCPMC6862078
OpenAlexW2982424467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.